Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

(2020) Daniel Blanco-Melo et al.   CELL

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

(2020) Ruggero Capra et al.   European Journal of Internal Medicine

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

(2020) Corrado Campochiaro et al.   European Journal of Internal Medicine

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

(2020) Tobias Herold et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Clinical and immunological features of severe and moderate coronavirus disease 2019

(2020) Guang Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

(2020) T. Klopfenstein et al.   MEDECINE ET MALADIES INFECTIEUSES

Cytokine release syndrome in severe COVID-19

(2020) John B. Moore et al.   SCIENCE

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

(2020) Marta Colaneri et al.   Microorganisms

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

(2020) Emily C Somers et al.   CLINICAL INFECTIOUS DISEASES

Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study

(2020) Krzysztof Tomasiewicz et al.   Expert Review of Anti-Infective Therapy

Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab

(2020) Annette Langer-Gould et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

IL-6–based mortality risk model for hospitalized patients with COVID-19

(2020) Rocio Laguna-Goya et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

(2020) Oscar Moreno-Pérez et al.   JOURNAL OF AUTOIMMUNITY

Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients

(2020) Lorenzo M. Canziani et al.   JOURNAL OF AUTOIMMUNITY

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

(2020) Roberto Rossotti et al.   JOURNAL OF INFECTION

Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6

(2020) Luca Quartuccio et al.   JOURNAL OF MEDICAL VIROLOGY

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

(2020) Alexandre B. Cavalcanti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

(2020) Maria Nicola et al.   International Journal of Surgery

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial

(2020) Remo H M Furtado et al.   LANCET

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

(2020) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

A living WHO guideline on drugs for covid-19

(2020) François Lamontagne et al.   BMJ-British Medical Journal

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

(2020) Shruti Gupta et al.   JAMA Internal Medicine

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

(2020) Olivier Hermine et al.   JAMA Internal Medicine

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia

(2020) Carlo Salvarani et al.   JAMA Internal Medicine

The role of IL-6 in host defence against infections: immunobiology and clinical implications

(2017) Stefan Rose-John et al.   Nature Reviews Rheumatology

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD